KR20170029577A - B형 간염 및 d형 간염 바이러스 감염의 치료 방법 - Google Patents

B형 간염 및 d형 간염 바이러스 감염의 치료 방법 Download PDF

Info

Publication number
KR20170029577A
KR20170029577A KR1020177003538A KR20177003538A KR20170029577A KR 20170029577 A KR20170029577 A KR 20170029577A KR 1020177003538 A KR1020177003538 A KR 1020177003538A KR 20177003538 A KR20177003538 A KR 20177003538A KR 20170029577 A KR20170029577 A KR 20170029577A
Authority
KR
South Korea
Prior art keywords
hbv
nucleic acid
acid polymer
seq
phosphorothioated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177003538A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 베일런트
Original Assignee
레플리코르 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170029577(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레플리코르 인코포레이티드 filed Critical 레플리코르 인코포레이티드
Priority to KR1020237015821A priority Critical patent/KR102734495B1/ko
Publication of KR20170029577A publication Critical patent/KR20170029577A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y10S514/894—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
KR1020177003538A 2014-07-10 2015-07-07 B형 간염 및 d형 간염 바이러스 감염의 치료 방법 Ceased KR20170029577A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237015821A KR102734495B1 (ko) 2014-07-10 2015-07-07 B형 간염 및 d형 간염 바이러스 감염의 치료 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US62/022,846 2014-07-10
US201462091943P 2014-12-15 2014-12-15
US62/091,943 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015821A Division KR102734495B1 (ko) 2014-07-10 2015-07-07 B형 간염 및 d형 간염 바이러스 감염의 치료 방법

Publications (1)

Publication Number Publication Date
KR20170029577A true KR20170029577A (ko) 2017-03-15

Family

ID=55063440

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177003538A Ceased KR20170029577A (ko) 2014-07-10 2015-07-07 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
KR1020237015821A Active KR102734495B1 (ko) 2014-07-10 2015-07-07 B형 간염 및 d형 간염 바이러스 감염의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237015821A Active KR102734495B1 (ko) 2014-07-10 2015-07-07 B형 간염 및 d형 간염 바이러스 감염의 치료 방법

Country Status (34)

Country Link
US (1) US9603865B2 (https=)
EP (1) EP3166615B1 (https=)
JP (2) JP2017521433A (https=)
KR (2) KR20170029577A (https=)
CN (2) CN106659730A (https=)
AU (1) AU2015286199B2 (https=)
BR (1) BR112017000320B1 (https=)
CA (1) CA2954182C (https=)
CL (1) CL2017000008A1 (https=)
CU (1) CU20170001A7 (https=)
CY (1) CY1126361T1 (https=)
DK (1) DK3166615T3 (https=)
DO (1) DOP2017000002A (https=)
EA (1) EA036745B1 (https=)
EC (1) ECSP16097355A (https=)
ES (1) ES2963814T3 (https=)
FI (1) FI3166615T3 (https=)
HK (1) HK1231402A1 (https=)
HR (1) HRP20231400T1 (https=)
HU (1) HUE064449T2 (https=)
IL (1) IL249660B (https=)
LT (1) LT3166615T (https=)
MD (1) MD4760C8 (https=)
MX (1) MX381042B (https=)
MY (1) MY178087A (https=)
PH (1) PH12017500010B1 (https=)
PL (1) PL3166615T3 (https=)
PT (1) PT3166615T (https=)
RS (1) RS64833B1 (https=)
SG (1) SG11201700073PA (https=)
SI (1) SI3166615T1 (https=)
SM (1) SMT202300380T1 (https=)
TW (1) TWI766831B (https=)
WO (1) WO2016004525A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211783A1 (es) * 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN113620993A (zh) * 2020-05-07 2021-11-09 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦d晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
JP2024527380A (ja) 2021-07-09 2024-07-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド 腎機能障害を有する個体へのオリゴヌクレオチドの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
BR0314236A (pt) 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
US9474793B2 (en) * 2005-02-22 2016-10-25 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
BR112013003875B1 (pt) 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
WO2012058210A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
SMT202100319T1 (it) * 2012-05-18 2021-09-14 Replicor Inc Composizioni e metodi del complesso oligonucleotide chelato polipeptidico
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
SG11201501255PA (en) * 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
LT3166615T (lt) 2024-01-25
MY178087A (en) 2020-10-02
EA201790160A1 (ru) 2017-06-30
WO2016004525A1 (en) 2016-01-14
MD4760B1 (ro) 2021-07-31
KR20230070330A (ko) 2023-05-22
BR112017000320A2 (pt) 2017-11-07
US9603865B2 (en) 2017-03-28
HRP20231400T1 (hr) 2024-02-16
MX381042B (es) 2025-03-12
PH12017500010A1 (en) 2017-05-15
RS64833B1 (sr) 2023-12-29
DK3166615T3 (da) 2023-11-13
NZ727583A (en) 2024-08-30
EP3166615A1 (en) 2017-05-17
JP2017521433A (ja) 2017-08-03
MD20170014A2 (ro) 2017-07-31
MX2017000053A (es) 2017-05-01
CN106659730A (zh) 2017-05-10
HUE064449T2 (hu) 2024-03-28
EP3166615A4 (en) 2018-01-17
JP6922030B2 (ja) 2021-08-18
SMT202300380T1 (it) 2024-01-10
ECSP16097355A (es) 2017-03-31
CN113750112A (zh) 2021-12-07
EP3166615B1 (en) 2023-08-09
MD4760C8 (ro) 2022-02-28
ES2963814T3 (es) 2024-04-02
JP2020143065A (ja) 2020-09-10
IL249660A0 (en) 2017-02-28
CA2954182C (en) 2023-08-15
PL3166615T3 (pl) 2024-02-19
PT3166615T (pt) 2023-11-13
DOP2017000002A (es) 2017-03-15
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
US20160008393A1 (en) 2016-01-14
CL2017000008A1 (es) 2017-06-09
TWI766831B (zh) 2022-06-11
FI3166615T3 (fi) 2023-11-06
PH12017500010B1 (en) 2022-07-29
TW201613617A (en) 2016-04-16
BR112017000320B1 (pt) 2023-02-07
KR102734495B1 (ko) 2024-11-25
AU2015286199A1 (en) 2017-02-23
AU2015286199B2 (en) 2020-05-14
EA036745B1 (ru) 2020-12-16
SI3166615T1 (sl) 2023-12-29
HK1231402A1 (zh) 2017-12-22
CA2954182A1 (en) 2016-01-14
CY1126361T1 (el) 2026-02-25
SG11201700073PA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
KR20170029577A (ko) B형 간염 및 d형 간염 바이러스 감염의 치료 방법
TWI620568B (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
CN114057816B (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
EA039949B1 (ru) Способы лечения инфекций вирусом гепатита в и гепатита d

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170208

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200513

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220427

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221024

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220427

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20221024

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220627

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170213

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230209

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230125

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20221024

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220627

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220427

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170213

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230510